Health Canada approved Opsens’ (TSX:OPS; OTCQX:OPSSF) diastolic pressure ratio (dPR) proprietary resting index, which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide treatment of patients with coronary heart disease.
The measurement of fractional flow reserve (FFR), taken when the heart is stimulated, is the gold standard among doctors for assessing intracoronary pressure. Opsens’ dPR has been developed to meet demand by cardiologists for a way to measure intracoronary pressure with the heart at rest.
“Accuracy of the pressure measurement becomes even more critical when pressure is measured with the heart at rest,” Louis Laflamme, president and CEO, said in a statement. “The approval of Opsens’ dPR is a milestone, as it provides us access to a new growing segment of the market.”
dPR is now authorized for sale in Canada and Japan and is under review with regulatory agencies in the U.S. and Europe, he added.
